Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06626490

Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants

Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants — Recruiting • NCT06626490.

📅 01 May 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06626490
Start
2026-04-07
Completion
2033-03
ClinicaliQ Trial Snapshot
  • Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants — Recruiting • NCT06626490.
  • Long-term safety and performance study of different Prevision hip stem variants in routine clinical practice.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The study design is confirmative for non-inferiority of the functional outcome of the implants and is intended to examine the safety and performance of the Prevision hip stem. The study is an observational post-market clinical follow-up study, and the study sites chose the stem variant depending on their own routine and indication. Conditions: Revision Total Hip Arthroplasty, Periprosthetic Fracture of Hip Interventions: Prevision Revision hip endoprosthesis stem implantation Lead Sponsor: Aesculap AG Planned Enrollment: 120 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn